Several treatment options are currently available for patients with metastatic castration-resistant prostate cancer in routine clinical practice.

However, clear standards of sequential use of registered drugs have not yet been developed. Affecting bone metastases, radium-223 is one of therapeutic options for patients with castration-resistant prostate cancer and bone metastases, which was included in foreign and Russian guidelines for prostate cancer management. This article analyzes the results of treatment with radium-223 in patients with metastatic castration-resistant prostate cancer in foreign non-interventional clinical trials conducted in routine clinical practice. These trials confirmed high efficacy and safety of radium-223 demonstrated earlier in the ALSYMPCA trial. Some protocols ensured better overall survival rates and lower incidence of symptomatic skeletal events and adverse events than those in the registration study.

Source: Matveev V.B., Markova A.S. Efficacy and safety of radium-223 in routine clinical practice. Cancer Urology. 2020;16(4):129-135. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-4-129-135